Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-04-21 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：董事会提名委员会关于补选第四届董事会独立董事的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the Board Nomination Committee regarding the nomination of an independent director candidate for the company's fourth board. It references compliance with company law, stock exchange listing rules, and internal company bylaws. The content focuses on the qualifications and independence of the director candidate and the committee's recommendation to the board. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of any other regulatory filings or legal proceedings. This document is best classified as Board/Management Information (MANG) because it concerns board member nomination and related governance matters.
2025-04-21 Chinese
美迪西：2025年第二次职工代表大会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed at the 2025 second employee representative meeting of Shanghai Medicilon Biopharmaceutical Co., Ltd. It discusses the approval of an employee stock ownership plan draft and its summary. The document is a formal announcement of a meeting decision and does not contain financial statements or detailed financial data. It is not a full report but an announcement of a corporate governance event related to employee stock plans. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is about the approval process and not the actual issuance or financing event yet.
2025-04-21 Chinese
美迪西：2024年度独立董事述职报告（许金叶-已届满离任）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" (2024 Annual Independent Director's Work Report) of Shanghai Medicilon Inc. It is a detailed report by an independent director about their duties, attendance at meetings, communication with auditors, oversight of financial reports, and other governance-related activities during the year 2024. The content focuses on the independent director's role, supervision, and evaluation of company governance and financial reporting, rather than presenting financial statements or audit opinions themselves. This type of document is a management or governance-related report, specifically an independent director's annual work report. It does not contain full financial statements or audit opinions, so it is not an Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is not a simple announcement or certification, so it is not RPA or RNS. The best fitting category is Board/Management Information (MANG), as it relates to board-level reporting and management oversight information.
2025-04-21 Chinese
美迪西：第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fourth board of directors of Shanghai Medicilon Inc. It includes approvals of various reports and proposals related to the 2024 fiscal year, such as the 2024 Board Work Report, General Manager Work Report, Independent Directors' Report, Audit Committee reports, 2024 Financial Statements, Profit Distribution Plan, 2024 Annual Report, Employee Stock Ownership Plan, and other governance and operational matters. The document repeatedly states that these resolutions require submission to the shareholders' meeting for approval. It also references multiple reports and announcements published separately on the Shanghai Stock Exchange website, indicating that this document itself is a board meeting resolution announcement rather than the full reports. The document is lengthy (9890 characters) and contains detailed voting results and descriptions of board decisions, which is typical for a Board/Management Information filing. It is not the full Annual Report (10-K), nor is it a simple announcement of report publication (RPA). It is not a call transcript, earnings release, or other categories. Therefore, the best classification is Board/Management Information (MANG).
2025-04-21 Chinese
美迪西：关于2024年度计提资产减值准备及核销资产的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the 2024 fiscal year asset impairment provisions and asset write-offs. It details the amounts of impairment losses and write-offs, references accounting standards, and includes opinions from the audit committee, board of directors, and supervisory board. The document is relatively short (2049 characters) and focuses on specific accounting adjustments rather than presenting a full financial report. It is not a full annual or interim report, nor a certification or regulatory filing. The content fits best with a Capital/Financing Update (CAP) as it relates to financial adjustments impacting the company's capital and financial position, specifically asset impairments and write-offs. Therefore, the appropriate classification is CAP with high confidence.
2025-04-21 Chinese
美迪西：2024年度环境、社会与公司治理（ESG）报告
Environmental & Social Information Classification · 95% confidence The document is titled "2024 年度环境、社会和公司治理（ESG）报告" which translates to "2024 Environmental, Social and Corporate Governance (ESG) Report." It covers topics such as ESG governance, environmental management, social responsibility, corporate governance, and related data. The report period is the full year 2024, and it is prepared according to Shanghai Stock Exchange regulations on sustainability reporting. The content includes detailed ESG strategy, governance structure, stakeholder communication, materiality analysis, risk and opportunity assessments, and progress on ESG goals. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive report on ESG performance and governance. This matches the definition of Environmental & Social Information (Code: SR), which covers reports detailing the company's performance on Environmental, Social, and Governance factors. Therefore, the document should be classified as SR with high confidence.
2025-04-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.